Health & bio
Lantus Interchangeable Biosimilar Langlara Approved April 29
Insulin glargine-aldy (Langlara) received approval on April 29 as an interchangeable biosimilar to Lantus, adding pricing pressure to diabetes care.
Primary sources · 1
Insulin glargine-aldy (Langlara) received approval on April 29 as an interchangeable biosimilar to Lantus, adding pricing pressure to diabetes care.
7 must-reads · 17 fields · tracked storylines delivered to your inbox daily. Pick only the fields you want; unsubscribe anytime.